HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Stewart, D. Articles by Matlashewski, G. Search for Related Content PubMed PubMed Citation Articles by Stewart, D. Articles by Matlashewski, G. Agricola Articles by Stewart, D. Articles by Matlashewski, G.

Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18

Shirin Kazemi^2,

Suiyang Li^2,,

¹ Institute of Parasitology, MacDonald Campus, McGill University, Montreal, Canada, H9X 3V9
² Lady Davis Institute for Medical Research, McGill University, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada, H3T 1E2
³ International Centre for Genetic Engineering and Biotechnology, Padriciano 99, I-34012 Trieste, Italy
⁴ Department of Microbiology and Immunology, McGill University, 3775 University Street, Room 511, Montreal, Canada, H3A 2B4

Correspondence
Greg Matlashewski
greg.matlashewski{at}mcgill.ca

Human papillomaviruses (HPVs) are aetiological agents for genital warts and cervical cancer, the different pathologies of which are dependent on the type of HPV infection. Oncogenic HPV types associated with cancer are carcinogens by virtue of their oncogene products, which target key regulators of cell proliferation and apoptosis. The viral E6 protein from oncogenic HPV types plays a central role in carcinogenesis by exploiting the cellular proteasome degradation pathway in order to mediate the degradation of cellular proteins, most notably the prototype tumour suppressor protein p53. Much less is known about the cellular targets of E6 from the non-oncogenic HPV types associated with genital warts. It is also unclear what factors influence the level and stability of the viral E6 proteins in cells. This report demonstrates that both oncogenic and non-oncogenic HPV E6 proteins (from types 18 and 11, respectively) are ubiquitinated and targeted for degradation by the 26S proteasome. E6 domains required for the induction of p53 or DLG degradation, or E6AP binding, are not involved in proteasome-mediated degradation of HPV-18 E6. These results provide insight into the cellular modulation of E6 protein levels from both high-risk and low-risk HPV types.

Shirin Kazemi and Suiyang Li contributed equally to this work.

Present address: Department of Biochemistry, McIntyre Medical Building, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada, H3G 1Y6.

This article has been cited by other articles:

				J. F. Raven, D. Baltzis, S. Wang, Z. Mounir, A. I. Papadakis, H. Q. Gao, and A. E. Koromilas PKR and PKR-like Endoplasmic Reticulum Kinase Induce the Proteasome-dependent Degradation of Cyclin D1 via a Mechanism Requiring Eukaryotic Initiation Factor 2{alpha} Phosphorylation J. Biol. Chem., February 8, 2008; 283(6): 3097 - 3108. [Abstract] [Full Text] [PDF]

				C. H. Storrs and S. J. Silverstein PATJ, a Tight Junction-Associated PDZ Protein, Is a Novel Degradation Target of High-Risk Human Papillomavirus E6 and the Alternatively Spliced Isoform 18 E6 J. Virol., April 15, 2007; 81(8): 4080 - 4090. [Abstract] [Full Text] [PDF]

				D. Stewart, A. Ghosh, and G. Matlashewski Involvement of Nuclear Export in Human Papillomavirus Type 18 E6-Mediated Ubiquitination and Degradation of p53 J. Virol., July 15, 2005; 79(14): 8773 - 8783. [Abstract] [Full Text] [PDF]